Shots:
- DAAN Biotherapeutics & GC Cell have entered into an exclusive technology transfer agreement for tumor antigen-specific antibody sequence
- As per the agreement, DAAN has granted GC Cell exclusive rights to use its antibody sequence, which targets a protein highly overexpressed in major solid tumors, for research & development of CAR-T & CAR-NK therapies
- Financial terms of the agreement remain undisclosed but incl. upfront payment along with development & commercial milestones, plus sales-based royalties to DAAN Biotherapeutics
Ref: Prnewswire | Image: DAAN Biotherapeutics & GC Cell
Related News:- Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
